Viral hepatitis: A narrative review of hepatitis A–E

Table 2 Drugs in pipeline for hepatitis B virus

drug class	Drug	Company	Phase
Core protein inhibitors	AB-506	Arbutus Biopharma	1
	ABI-H0731	Assembly Biosciences	1,2
	ABI-H2158	Assembly Biosciences	1
	EDP-514	Enanta Pharmaceuticals	1
	JNJ-6379	Johnson & Johnson	1,2
	JNJ-0440	Johnson & Johnson	1
	RO7049389	Roche	1
siRNA, antisense RNA	AB-729	Arbutus Biopharma	1
	DCR-HBVS	Dicerna Pharmaceuticals	1
	GSK/IONIS-HBV-LRx	Ionis/GlaxoSmithKline	1,2
	IONIS-HBVRx	Ionis/GlaxoSmithKline	1,2
	JNJ-3989 (ARO-HBV)	Johnson & Johnson	1,2
	RO7062931	Roche	1
	Vir-2218 (ALN-HBV02)	Vir Biotechnology/Alnylam	1
pol/RT inhibitor	Tenofovir exalidex	ContraVir Pharmaceuticals	1,2
HBsAg secretion inhibitors	REP-2139	Replicor	1,2
	REP-2165	Replicor	1,2
HBV entry inhibitor	Bulevirtide	Hepatera Ltd	1,2
TLR-7 agonists	AL-034	Johnson & Johnson/Alios	1
	RG-7854	Roche	1
	RO7020531	Roche	1
TLR-8 agonist	GS-9688	Gilead Sciences	1,2
Therapeutic vaccines	AIC-649	AiCuris	1
	INO-1800	Inovio Pharmaceuticals	1
	TG1050	Transgene	1
RIG-I and NOD2 agonist	Inarigivir	Spring Bank	1,2
Apoptosis inducer	APG-1387	Ascentage Pharma	1
FXR agonist	EYP-001	Enyo Pharma	1,2

HBV: hepatitis B virus; HBsAg: Hepatitis B surface antigen; TLR: Toll-like receptor.